NFE2L2 and cancer: In addition, evidence from studies in cancer cell lines and in experimental animals supported the capability of NRF2 to enhance drug resistance against a diverse range of drugs, such as cisplatin, carboplatin, 5‐fluorouracil, paclitaxel, bleomycin, doxorubicin, and etoposide [9,10].